OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products ...
예상 EPS $-0.23 · 매출 $68.49M · 3 명의 애널리스트
예상 EPS $-0.25 · 매출 $68.61M · 3 명의 애널리스트
예상 EPS $-1.22 · 매출 $266.98M · 4 명의 애널리스트
예상 EPS $-0.34 · 매출 $66.70M · 1 명의 애널리스트
EPS $-0.46 · 매출 $52.41M
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $236.3M | +15.4% | +18.8% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-39.6M | -4.8% | +33.0% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +73.1% | +0.6% | +1.6% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -12.3% | +14.9% | +58.9% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -16.8% | +9.2% | +43.6% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-16.0M | +61.4% | +38.2% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -6.8% | +66.5% | +48.0% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 28.8% | +26.4% | -15.0% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 5.55x | -20.5% | -8.3% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $508.6M | +7.5% | +1.8% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -1.69 vs -1.25 | -34.9% | -0.30 vs -0.23 | -33.3% |
| 매출 서프라이즈 | $236.3M vs $234.9M | +0.6% | $70.5M vs $68.5M | +2.9% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Squadron Capital LLC | 10 percent owner | Common Stock | D | 10,131 | $23.10 |
| Sep 1, 2026 | Pritzker Jennifer N. | 10 percent owner | Common Stock | D | 10,131 | $23.10 |
| Sep 1, 2026 | Pelizzon David R | director, 10 percent owner: | Common Stock | D | 10,131 | $23.10 |
| Aug 28, 2026 | Squadron Capital LLC | 10 percent owner | Common Stock | D | 326,700 | $23.04 |
| Aug 28, 2026 | Pritzker Jennifer N. | 10 percent owner | Common Stock | D | 326,700 | $23.04 |
Operator: Good afternoon and welcome to the OrthoPediatrics Corp. Second Quarter 2026 Conference Call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Trip Taylor from the Gilmartin Group for a few introductory comments. Philip Taylor Thank you for joining today's call. With me from the company are David Bailey, President and Chief Executive Officer, and Fred Hite, Chief Operating and Financial Officer. Before we begin today, let me remind you that the company's remarks include forward-looking statements within the meaning of federal securities laws, including the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to numerous risks and uncertainties, and the company's actual results may differ materially. For a discussion of risk factors, I encourage you to review the company's most recent annual report on Form 10-K, which was filed with the SEC on March 4, 2026, and its subsequent quarterly reports on Form 10-Q. During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. The company believes these measures provide useful information for investors in evaluating its operations period over period. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure in its second quarter earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for OrthoPediatrics' financial results prepared in accordance with GAAP. In addition, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast today, August 4, 2026. Except as required by law, the company undertakes no obligation to revise or update any statements to reflect the events or circumstances taking place after the date of this call. With that, I'd like to turn the call over to David Bailey, President and Chief Executive Officer. David Bailey: Thanks, Trip. Good afternoon, everyone, and thank you for joining us today. I'll start with our most meaningful performance metric, patient impact. In the second quarter, we helped nearly 46,000 children, another new record, increasing our cumulative impact to 1.4 million kids helped. At OrthoPediatrics, we are entirely committed to improving clinical outcomes for kids through our dedicated technology, targeted innovation, and unrivaled level of focus on serving our pediatric patients. Our second quarter results further validate the strategy we have been executing over the past several years. We continue to gain share across our core markets. OPSB is emerging as a meaningful driver of both growth and profitability. And our multi-year product launch super …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
David R. Bailey | President, Chief Executive Officer & Director | USD 886,281 | Male | 1979 | Active |
Fred L. Hite | Chief Financial Officer, Principal Financial & Accounting Officer, Chief Operating Officer and Director | USD 808,569 | Male | 1968 | Active |
Joseph W. Hauser | President of Trauma, Deformity Correction & OPSB | USD 666,463 | Male | 1982 | Active |
Gregory A. Odle | President of Scoliosis | USD 525,757 | Male | 1970 | Active |
Daniel J. Gerritzen | Executive Vice President of Legal, General Counsel & Secretary | USD 524,637 | Male | 1970 | Active |
Mark C. Throdahl | Executive Chairman | USD 27,500 | Male | 1951 | Active |
Kevin L. Unger MBA/MSHA | President of Enabling Technologies | USD 22,500 | Male | 1972 | Active |
Ray Garrison | Senior Vice President of Quality & Regulatory and Clinical | — | — | — | Active |
Mark Karshner | Senior Vice President of International Sales | — | Male | — | Active |
Intercontinental Exchange, Inc. (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets, today
Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology Successful Limited Launch Demonstrates Demand for Innovative Pediatric-Specific Hip Plating Technology
OrthoPediatrics NASDAQ: KIDS reported record revenue, adjusted EBITDA and number of children helped during the second quarter, as the pediatric orthopedic device company began to see early contributions from its newer “super cycle” products, Chief Executive Officer Dave Bailey said at the Canaccord Genuity Growth Conference.
Intercontinental Exchange, Inc. (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets, today
OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript
